Facebook Stock – Top Research Reports for UnitedHealth, Pfizer & Accenture
Friday, April 16, 2021
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Pfizer (PFE), and Accenture (ACN). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of UnitedHealth have outperformed the Zacks Medical Insurance industry over the past year (+33.4% vs. +29.1%). The Zacks analyst believes that the company’s top line is bolstered by numerous acquisitions, new deals, renewed agreements and expansion of service offerings.
Its solid health services segment provides significant diversification benefits. Further, the company remains well poised to gain from its government business. A sturdy balance sheet and consistent cash flow generation are other positives, which led to a solid capital position.
This enables the company to engage in share buybacks and dividend payments. A strong 2021 view buoys investor optimism on the stock. However, the company is witnessing a slowdown in international and commercial business.
(You can read the full research report on UnitedHealth here >>>)
Pfizer shares have gained +0.8% over the last six months against the Zacks Large-Cap Pharmaceuticals industry’s gain of +6.5%. The Zacks analyst believes that the Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Further, Pfizer expects strong growth of key brands like Ibrance, Inlyta and Eliquis to drive sales. Furthermore, its COVID-19 vaccine candidate is now approved for emergency use in several countries.
However, currency headwinds and pricing pressure are key top-line headwinds. Meanwhile, its Upjohn unit was a cash rich business and its divestiture will reduce the company’s cash flow.
(You can read the full research report on Pfizer here >>>)
Shares of Accenture have gained +12.7% in the past three months against the Zacks Consulting industry’s gain of +12.3%. The Zacks analyst believes that the company has been steadily gaining traction in its outsourcing and consulting businesses.
Moreover, it has been strategically enhancing its cloud and digital marketing suite through acquisitions and partnerships. Accenture’s strong operating cash flow has helped it reward its shareholders in the form of dividends as well as pursue opportunities in areas that show true potential.
However, pricing pressure due to significant competition from strong companies like Genpact, Cognizant and Infosys, remains a concern. Global presence exposes it to foreign currency exchange rate fluctuations. Buyout-related integration risks continue to remain a concern.
(You can read the full research report on Accenture here >>>)
Other noteworthy reports we are featuring today include Wells Fargo (WFC), SAP SE (SAP) and Uber Technologies (UBER).
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today’s Must Read
Strong Service and Benefit Business Aids UnitedHealth (UNH)
Key Brands & COVID-19 Vaccine to Drive Pfizer’s (PFE) Sales
Accenture (ACN) Rides on Acquisitions Amid Pricing Pressure
Cost Control, Streamlining Initiatives Aid Wells Fargo (WFC)
Per Zacks analyst, Wells Fargo’s cost-savings measures to drive efficiency with a streamlined organizational structure, are encouraging.
Growth in S/4HANA Platform & Cloud Initiatives Benefit SAP
Per the Zacks analyst, robust uptake of S/4HANA and other cloud-based offerings have driven SAP’s top line. High demand for Ariba and Fieldglass solutions also bode well.
Delivery Business Backs UBER Amid Mobility Weakness
The Zacks analyst is optimistic about the continued growth in Uber’s delivery segment. However, the mobility business continues to be weak despite having improved from the coronavirus-led slump.
Infosys (INFY) Gains From Strong Demand For Its Services
Per the Zacks analyst, focus on Agile Digital and AI-driven Core services is aiding Infosys’ top line. Strong demand for its services in cloud, IoT, cybersecurity, data, and analytics is a key driver.
Growth Projects Aid Newmont (NEM) Amid Cost Woes
The Zacks analyst believes that Newmont will gain from a number of growth projects amid headwind from higher production costs.
Customer Wins, Focus on Renewables Aid Xcel Energy (XEL)
Per Zacks analyst, Xcel Energy’s rising customer base, investments and focus on renewable growth act as tailwinds while cyber risks and failure of transmission and distribution lines pose threats.
Baker Hughes (BKR) Gains From LNG Terminal Supply Contracts
Per the Zacks analyst, Baker Hughes is well placed to capitalize on multiple LNG terminal contracts around the globe.
Darden (DRI) Rides on Cheddar’s Business Model Transformation
Per the Zacks analyst, Darden continues to benefit from Cheddar’s business model transformation, sales-building initiatives, technology-driven moves, and efforts to develop the core menu.
Acuity Brands (AYI) Rides on Diversified & Innovative Portfolio
Per the Zacks analyst, Acuity Brands’ diverse portfolio of innovative lighting and energy-efficient luminaries are major positives. Also, the company’s decision of structural re-alignment bodes well.
Kinsale Capital (KNSL) Continues to Gain From E&S Lines Market
Per the Zacks analyst, Kinsale is set to grow on solid excess and surplus lines (E&S) market due to improved margins and lower loss ratios. This has led to strong underwriting results.
Competition, Delayed Deals Hurt Science Applications (SAIC)
Per the Zacks analyst, Science Applications is facing delays in contracts due to ongoing protests with the Government Accountability Office. Moreover, neck-and-neck competition with CACI is a concern.
Weak End Markets & Rising Costs Hurt Altra Industrial (AIMC)
Per the Zacks analyst, Altra Industrial Motion is struggling with weakness across its metals, mining, and oil & gas end markets amid the coronavirus outbreak. High operating costs remain concerning.
Pandemic Led High Costs to Ail Rite Aid’s (RAD) Performance
Per the Zacks analyst, COVID-19 related costs woes and lesser cases of cough, cold, and flu are likely to dent Rite Aid’s fiscal 2022 performance. Also, delayed elective procedures remain a concern.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Wells Fargo & Company (WFC): Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH): Get Free Report
Uber Technologies, Inc. (UBER): Free Stock Analysis Report
SAP SE (SAP): Free Stock Analysis Report
Pfizer Inc. (PFE): Get Free Report
Accenture PLC (ACN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Facebook Stock – Top Research Reports for UnitedHealth, Pfizer & Accenture
tags: Facebook Stock